2020
DOI: 10.1101/2020.08.13.20174094
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Assessing the efficacy and safety of angiotensinogen inhibition using human genetics

Abstract: Background Novel angiotensinogen (AGT) inhibitors are in early clinical development for treatment of hypertension. Evidence that this therapeutic approach will safely reduce risk of cardiovascular outcomes in humans is limited. We leveraged genetic data from more than one million individuals to characterise the effects of AGT inhibition. Methods We identified a genetic instrument for AGT inhibition from systolic blood pressure (SBP) genome-wide association study data, and investigated its relationship with A… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 89 publications
(95 reference statements)
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?